Professor Stephen Jackson captivated the audience on the final day of the European Society for the Study of Tourette Syndrome (ESSTS) conference with a presentation on the clinical trial results of the Neupulse device in Tourette Syndrome.
During his talk, Professor Jackson gave the background into using the peripheral nervous system to stimulate the brain to reduce the urge to tic and tic frequency. He provided a comprehensive overview of the findings from the groundbreaking clinical trial, which were recently published in the prestigious Journal of Neuropsychology in May 2023. This exciting breakthrough science underpins the work and product development at Neupulse.
Company number: 13198315
Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham
England
NG7 2TU
Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd